Description
EMT6/AR1.0 was derived from the mouse mammary tumour cell line EMT6/P by growth in increasing amounts of doxorubicin over a period of 8 weeks. The cell line showed a 40-fold greater resistance to doxorubicin, which cell line is also known as adriamycin. The line was reported to express a classical multi-drug resistance (MDR) phenotype with hyperexpression of membrane P-glycoprotein and a spectrum of cross-resistance e.g. against vincristine and colchicine. Overexpression of CP22 (sorcin) and mdr 1a gene was reported. Cells were shown to have a reduced intracellular drug accumulation and exhibit a doubling time of 12-15 hours. It is recommended to culture the cells without drug after resuscitation until the first passage.
Adherent Suspension
Adherent
Suggested Medium
MEM (EBSS) + 2mM Glutamine + 1% Non Essential Amino Acids (NEAA) +1.0 µg/ml doxorubicin + 10% Foetal Bovine Serum (FBS).
Quality Control
EMT6/AR1 Cell Line was tested and found to be free of mycoplasma, bacterial, viruses, and other toxins. All cells were above 95% viability before freezing.
Morphology
Epithelial-like
Shippment
EMT6/AR1 Cell Line will be shipped using dry ice.
Storage
Store the cell lines in liquid nitrogen vapor (less than -130°C)
Warranty
EMT6/AR1 Cell Line is for research use only
